Editorial: HIV-based lentiviral vectors for anti-HIV gene therapy

Future Virology

Volumn 5, Issue 4, 2010, Pages 367-369

  Berkhout, Ben ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; LENTIVIRUS VECTOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; VIRUS GLYCOPROTEIN;

CD34 SELECTION; CD4+ T LYMPHOCYTE; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RISK REDUCTION; RNA INTERFERENCE; VESICULAR STOMATITIS VIRUS; VIRAL GENE THERAPY; VIRUS DNA CELL DNA INTERACTION;

EID: 77954945621     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.30     Document Type: Editorial

References (18)

1. Cartier N, Hacein-Bey-Abina S, Bartholomae CC etal.: Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326(5954), 818-823 (2009).
2. DeVincenzo J, Cehelsky JE, Alvarez R et at.: Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 77(3), 225-231 (2008).
3. Berkhout B: Toward a durable anti-HIV gene therapy based on RNA interference. Ann. NY Acad. Sci. 1175, 3-14 (2009).
4. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B: Human immunodeficiency virus type 1 escape from RNA interference. J. Virol 77(21), 11531-11535 (2003).
5. Das AT, Brummelkamp TR, Westerhout EM et at.: Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J. Virol. 78(5), 2601-2605 (2004).
6. Liu YP, Berkhout B: Lentiviral delivery of RNAi effectors against HIV-1. Curr. Top. Med. Chem. 9(12), 1130-1143 (2009).
7. Barichievy S, Saayman S, Arbuthnot P, Weinberg MS: RNA interference-based gene expression strategies aimed at sustained therapeutic inhibition of HIV. Curr. Top. Med. Chem. 9(12), 1065-1078
8. Zhang J, Rossi JJ: Strategies in designing multigene expression units to downregulate HIV-1. Methods Mol. Biol. 623, 123-136
9. Westerhout EM, Berkhout B: A systematic analysis of the effect of target RNA structure on RNA interference. Nucleic Acids Res. 35(13), 4322-4330 (2007).
10. Liu YP, Vink M, Westerink JT et al.: Titers of lentiviral vectors encoding shRNAs and miRNAs are reduced by different mechanisms that require distinct repair strategies. RNA 16(7), 1328-1339 (2010).
11. Liu YP, von Eije KJ, Schopman NC et al.: Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol. Ther. 17(10), 1712-1723 (2009).
12. Ter Brake O, Konstantinova P, Ceylan M, Berkhout B: Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol. Ther. 14(6), 883-892 (2006).
13. Hutter G, Nowak D, Mossner M et al.: Long-term control of HIV by CCR5 A32/A32 stem-cell transplantation. N. Engl. J. Med. 360(7), 692-698 (2009).
14. Martinez MA, Gutierrez A, Armand-Ugon M et al.: Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 16(18), 2385-2390 (2002).
15. Shimizu S, Hong P, Arumugam B et al.: A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood 115(8), 1534-1544 (2010).
16. Lu X, Yu Q, Binder GK et al.: Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. J. Virol. 78(13), 7079-7088 (2004).
17. Marzio G, Verhoef K, Vink M, Berkhout B: In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies. Proc. Natl Acad. Sci. USA 98(11), 6342-6347 (2001).
18. Westerhout EM, Vink M, Haasnoot PC, Das AT, Berkhout B: A conditionally replicating HIV-based vector that stably expresses an antiviral shRNA against HIV-1 replication. Mol. Ther. 14(2), 268-275 (2006).